Pulmonary , Critical Care, and Sleep Medicine
Permanent URI for this collectionhttp://hdl.handle.net/10342/104
Browse
Recent Submissions
Item Open Access NAVIGATE 24-Month Results: Electromagnetic Navigation Bronchoscopy for Pulmonary Lesions at 37 Centers in Europe and the United States(2022) Bowling, Mark R.; Folch, Erik E.; et alItem Open Access Myeloid ABCG1 Deficiency Enhances Apoptosis and Initiates Efferocytosis in Bronchoalveolar Lavage Cells of Murine Multi-Walled Carbon Nanotube-Induced Granuloma Model(2022) Soliman, Eman; Bhalla, Sophia; Malur, Anagha; Ogburn, David; Leffler, Nancy; Thomassen, Mary Jane; Elhassanny, Ahmed E. M.; Malu, Achut G.Item Open Access Onset of Effect and Impact on Health-Related Quality of Life, Exacerbation Rate, Lung Function, and Nasal Polyposis Symptoms for Patients with Severe Eosinophilic Asthma Treated with Benralizumab (ANDHI): a Randomised, Controlled, Phase 3b Trial(2021) Mohan, Arjun; Harrison, Tim; Chanez, Pascal; Menzella, Francesco; Canonica, Giorgio Walter; Louis, Renaud; Cosio, Borja; Lugogo, Njira; Burden, Annie; Mcdermott, LawrenceItem Open Access Acute Motor Neuropathy with Quadriparesis following Treatment with Triple Tyrosine Kinase Inhibitor, Nintedanib(2021) Kunadu, Afua; Alqalyoobi, Shehabaldin; Frere, Robert C.; Obi, Ogugua NdiliItem Open Access Mitomycin Induced Pulmonary Veno-Occlusive Disease(2021) Kunadu, Afua; Labuschagne, Heloise; Maddipati, Veeranna; Stalls, J. Stephen; Thayyil, Abdullah; Falls, RandallItem Open Access The M2a Macrophage Phenotype Accompanies Pulmonary Granuloma Resolution in Mmp12 Knock-Out Mice Instilled with Multiwall Carbon Nanotubes(2021-10-13) Ogburn, David; Bhalla, Sophia; Leffler, Nan; Mohan, Arjun; Malur, Anagha; Malur, Achut G.; McPeek, Matthew; Barna, Barbara P.; Thomassen, Mary JaneItem Open Access Item Open Access Improved Respiratory Motion Tracking Through a Novel Fiducial Marker Placement Guidance System During Electromagnetic Navigational Bronchoscopy (ENB)(2019-07-11) Bowling, Mark R.; Walker, PaulItem Open Access Design of a Prospective, Multicenter, Global, Cohort Study of Electromagnetic Navigation Bronchoscopy(2016-04-26) Bowling, Mark R.Item Open Access Feasibility and Safety of the Transbronchial Access Tool for Peripheral Pulmonary Nodule and Mass(2017-08-01) Bowling, Mark R.; Anciano, Carlos J.Item Open Access Item Open Access Longitudinal Monitoring for the Emergence of Epidermal Growth Factor C797S Resistance Mutations in Non-Small Cell Lung Cancer Using Blood-Based Droplet Digital PCR(2019-01-01) Bowling, Mark R.; Arastu, Hyder; Walker, PaulItem Open Access Item Open Access Item Open Access Elevated MicroRNA-33 in Sarcoidosis and a Carbon Nanotube Model of Chronic Granulomatous Disease(2016-06-01) Bowling, Mark R.; Barna, Barbara P.; McPeek, Matthew; Malur, Anagha; Wingard, Christopher J.; Dobbs, Larry; Verbanac, Kathryn M.; Thomassen, Mary JaneItem Open Access Pleural Dye Marking of Lung Nodules by Electromagnetic Navigation Bronchoscopy(2019-09-02) Bowling, Mark R.Item Open Access Item Open Access Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease(2002-10-31) Nyce, Jonathan W.A composition comprises as the active agent a Non-glucocorticoid steroid, analogue thereof, a ubiquinone, or their salts, in an amount effective for reducing levels of, or hypersensitivity to, adenosine, increasing levels of lung surfactant or ubiquinone, or for preventing or treating respiratory, lung and cancer diseases. The present treatment is useful for treating asthma, rhinitis, COPD, CF, RDS, pulmonary fibrosis, cancer and other diseases.Item Open Access A case of successfully treated with voriconazole(2013-09) Rimawi, Bassam H.; Rimawi, Ramzy H.; Mirdamadi, Meena; Steed, Lisa L.; Marchell, Richard; Sutton, Deanna A.; Thompson, Elizabeth H.; Wiederhold, Nathan P.; Lindner, Jonathan R.; Boger, M. SeanItem Open Access Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasis(2012) Malur, Anagha; Kavuru, Mani S.; Marshall, Irene; Barna, Barbara P.; Huizar, Isham; Karnekar, Reema; Thomassen, Mary JaneRationale Pulmonary Alveolar Proteinosis (PAP) patients exhibit an acquired deficiency of biologically active granulocyte-macrophage colony stimulating factor (GM-CSF) attributable to GM-CSF specific autoantibodies. PAP alveolar macrophages are foamy, lipid-filled cells with impaired surfactant clearance and markedly reduced expression of the transcription factor peroxisome proliferator-activated receptor gamma (PPARγ) and the PPARγ-regulated ATP binding cassette (ABC) lipid transporter, ABCG1. An open label proof of concept Phase II clinical trial was conducted in PAP patients using rituximab, a chimeric murine-human monoclonal antibody directed against B lymphocyte specific antigen CD20. Rituximab treatment decreased anti-GM-CSF antibody levels in bronchoalveolar lavage (BAL) fluid, and 7/9 patients completing the trial demonstrated clinical improvement as measured by arterial blood oxygenation. Objectives This study sought to determine whether rituximab therapy would restore lipid metabolism in PAP alveolar macrophages. Methods BAL samples were collected from patients pre- and 6-months post-rituximab infusion for evaluation of mRNA and lipid changes. Results Mean PPARγ and ABCG1 mRNA expression increased 2.8 and 5.3-fold respectively (p ≤ 0.05) after treatment. Lysosomal phospholipase A2 (LPLA2) (a key enzyme in surfactant degradation) mRNA expression was severely deficient in PAP patients pre-treatment but increased 2.8-fold post-treatment. In supplemental animal studies, LPLA2 deficiency was verified in GM-CSF KO mice but was not present in macrophage-specific PPARγ KO mice compared to wild-type controls. Oil Red O intensity of PAP alveolar macrophages decreased after treatment, indicating reduced intracellular lipid while extracellular free cholesterol increased in BAL fluid. Furthermore, total protein and Surfactant protein A were significantly decreased in the BAL fluid post therapy. Conclusions Reduction in GM-CSF autoantibodies by rituximab therapy improves alveolar macrophage lipid metabolism by increasing lipid transport and surfactant catabolism. Mechanisms may involve GM-CSF stimulation of alveolar macrophage ABCG1 and LPLA2 activities by distinct pathways.